Overall, these trials, which have some caveats in terms of design, treatment selection and risk assessment, suggest that older patients with HR-positive, HER2-negative early breast cancer may have limited benefit from chemoendocrine therapy. This evidence concerns the gene ERBB2 and breast cancer.